The forecasted data for France's import of erythromycin from 2024 to 2028 indicates a significant downward trend. Starting from 2024, valued at 4.78 million USD, imports are projected to consistently decrease with an estimated value of just 0.56 million USD by 2028. The year-on-year percentage decrease is noticeable, showing France's declining demand or substitution towards erythromycin over the years. The compound annual growth rate (CAGR) over five years further accentuates this declining trend.
Future trends to watch for include potential innovations in alternative antibiotics, changes in France’s healthcare policies regarding antibiotic prescriptions, and shifts in global suppliers offering competitive products that could further influence import levels.
